Form 4: EKSO CFO Jerome Wong Granted 19,500 Vested RSUs

EKSO Bionics Holdings, Inc. Chief Financial Officer Jerome Wong received a grant of 19,500 fully vested restricted stock units on November 5, 2025, increasing his direct beneficial ownership.

Summary

• Jerome Wong, Chief Financial Officer of EKSO BIONICS HOLDINGS, INC. (EKSO), acquired 19,500 shares of common stock through a restricted stock unit (RSU) grant.
• The RSUs were granted on November 5, 2025, and were fully vested at the time of grant.
• The grant was approved by the Board of Directors under the Company's Amended and Restated 2014 Equity Incentive Plan.
• Following this transaction, Mr. Wong directly beneficially owns 37,297 shares of common stock.
• Additionally, Mr. Wong indirectly beneficially owns 2,876 shares through a 401(k) plan.
• All reported security amounts have been adjusted to reflect a 1-for-15 reverse stock split effected by the Issuer on June 2, 2025.

Sentiment

Score: 6

Explanation: The grant of fully vested equity to a key executive is a moderately positive signal, indicating management alignment and retention efforts, though it's a routine compensation event rather than a strategic announcement.

Positives

• The grant of 19,500 fully vested restricted stock units to the Chief Financial Officer aligns management's interests with shareholders.
• The immediate vesting of the RSUs indicates a direct and immediate increase in the officer's equity stake.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction reflects standard executive compensation practices within the biotechnology or medical device industry, where equity grants are common to incentivize and retain key management personnel. It does not provide broader insights into industry trends or competitive positioning.

Comparison to Industry Standards

• The grant of fully vested restricted stock units to a Chief Financial Officer is a common form of executive compensation, aligning with practices seen in comparable companies within the medical technology sector.
• The immediate vesting of the RSUs is a less common structure than phased vesting, but can be used to reward past performance or as a retention tool, similar to practices observed in some high-growth or turnaround situations.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of equity to a key executive can be viewed positively as it aligns management's interests with shareholder value creation. However, it also represents dilution, albeit typically planned within approved equity pools.
• Employees: This transaction primarily impacts the reporting executive and does not directly affect the broader employee base, though it signals the company's approach to executive compensation.

Key Dates

Recommendation

While the grant of fully vested restricted stock units to the CFO is a positive signal for management alignment and retention, a single Form 4 filing typically does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. It is an expected compensation event that reinforces the existing equity structure. Investors should 'hold' and consider this information in the broader context of the company's financial performance, strategic outlook, and overall market conditions.

Keywords

EKSO Bionics Holdings, EKSO, Jerome Wong, CFO, Restricted Stock Units, RSU, Insider Transaction, Equity Incentive Plan, Stock Grant, Beneficial Ownership, Reverse Stock Split